Latest Earnings Results: Q2 '26
Estimated EPS
$1.26
Reported EPS
$1.32
Surprise
+4.72%
Estimated Rev
$750.18M
Reported Rev
$773M
Surprise
+3.04%
• Reported GAAP EPS of $0.03 down -57.14% YoY • Reported revenue of $674M up 16.47% YoY • Royalty Pharma raised its full year 2026 guidance for Portfolio Receipts to between $3,400 million and $3,500 million, representing expected Royalty Receipts growth of 7% to 10% for Royalty Pharma.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $1.17 | -- | -- | N/A |
Q2 '26 | $1.26 | $1.32 | 4.72% | BEAT |
Q1 '26 | $1.10 | $1.30 | 17.31% | BEAT |
Q4 '25 | $1.29 | $1.47 | 14.02% | BEAT |
Q3 '25 | $0.99 | $1.17 | 18.08% | BEAT |